ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,00%
Bitcoin
68.010,51
0,42%
Brent Oil
81,295
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Pliant Therapeutics Inc (PLRX)

  7. Pliant Therapeutics Inc (PLRX) Notícias

PLRX

Pliant Therapeutics (PLRX)

Pliant Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PLRX
DataHoraFonteTítuloCódigoCompanhia
21/05/202419:50GlobeNewswire Inc.Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International ConferenceNASDAQ:PLRXPliant Therapeutics Inc
14/05/202408:43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLRXPliant Therapeutics Inc
14/05/202408:30GlobeNewswire Inc.Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary FibrosisNASDAQ:PLRXPliant Therapeutics Inc
07/05/202409:00GlobeNewswire Inc.Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™NASDAQ:PLRXPliant Therapeutics Inc
06/05/202417:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PLRXPliant Therapeutics Inc
06/05/202417:05GlobeNewswire Inc.Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:PLRXPliant Therapeutics Inc
06/05/202407:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLRXPliant Therapeutics Inc
01/05/202409:00GlobeNewswire Inc.Pliant Therapeutics to Participate in Upcoming Investor EventsNASDAQ:PLRXPliant Therapeutics Inc
27/03/202411:23GlobeNewswire Inc.Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International ConferenceNASDAQ:PLRXPliant Therapeutics Inc
12/03/202408:30GlobeNewswire Inc.Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary FibrosisNASDAQ:PLRXPliant Therapeutics Inc
27/02/202418:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PLRXPliant Therapeutics Inc
27/02/202418:03GlobeNewswire Inc.Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial ResultsNASDAQ:PLRXPliant Therapeutics Inc
26/02/202410:00GlobeNewswire Inc.Pliant Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:PLRXPliant Therapeutics Inc
14/02/202422:55Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PLRXPliant Therapeutics Inc
14/02/202410:52Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PLRXPliant Therapeutics Inc
04/02/202417:29GlobeNewswire Inc.Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver FibrosisNASDAQ:PLRXPliant Therapeutics Inc
03/01/202410:00GlobeNewswire Inc.Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PLRXPliant Therapeutics Inc
13/11/202318:30GlobeNewswire Inc.Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing CholangitisNASDAQ:PLRXPliant Therapeutics Inc
09/11/202318:05GlobeNewswire Inc.Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:PLRXPliant Therapeutics Inc
06/11/202310:00GlobeNewswire Inc.Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1NASDAQ:PLRXPliant Therapeutics Inc
31/10/202317:03GlobeNewswire Inc.Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of CancerNASDAQ:PLRXPliant Therapeutics Inc
19/10/202309:00GlobeNewswire Inc.Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023NASDAQ:PLRXPliant Therapeutics Inc
16/10/202317:05GlobeNewswire Inc.Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory OfficerNASDAQ:PLRXPliant Therapeutics Inc
26/09/202308:30GlobeNewswire Inc.Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver FibrosisNASDAQ:PLRXPliant Therapeutics Inc
25/09/202317:05GlobeNewswire Inc.Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing CholangitisNASDAQ:PLRXPliant Therapeutics Inc
15/09/202309:00GlobeNewswire Inc.Pliant Therapeutics Appoints Minnie Kuo as Chief Development OfficerNASDAQ:PLRXPliant Therapeutics Inc
11/09/202309:00GlobeNewswire Inc.Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023NASDAQ:PLRXPliant Therapeutics Inc
28/08/202317:05GlobeNewswire Inc.Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023NASDAQ:PLRXPliant Therapeutics Inc
09/08/202317:03GlobeNewswire Inc.Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:PLRXPliant Therapeutics Inc
09/08/202309:00GlobeNewswire Inc.Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary FibrosisNASDAQ:PLRXPliant Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PLRX

Seu Histórico Recente

BIT
F17920
Vontobel Financial Produ...
NASDAQI
CLOA
BlackRock AAA CLO ETF
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados